Vir Biotechnology, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Marianne de Backer
- Full Time Employees
- 367
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 499 Illinois Street San Francisco CA United States 94158
- IPO Date
- Oct 11, 2019
- CIK
- 0001706431
- Website
- vir.bio
- Similar Companies
- Business
- Vir Biotechnology, Inc. (Nasdaq: VIR) is a clinical-stage biopharmaceutical company that leverages immunology platforms to discover, develop and commercialize treatments for serious infectious diseases and oncology indications; its core technologies include a next-generation antibody platform and the PRO-XTEN protease-releasable masking technology exclusively licensed from Sanofi for oncology and infectious diseases. The company offers a deep pipeline of candidates such as tobevibart (an antibody incorporating Xencor's Xtend and other Fc technologies) combined with elebsiran for chronic hepatitis delta virus treatment in Phase 3 trials; VIR-5818, a dual-masked HER2-targeted T-cell engager in Phase 1 dose escalation with pembrolizumab for solid tumors; VIR-5500, a PSMA-targeted T-cell engager in Phase 1 with androgen receptor pathway inhibitors for prostate cancer; VIR-5525, an EGFR-targeted T-cell engager in Phase 1 monotherapy or with pembrolizumab; and preclinical efforts including undisclosed PRO-XTEN T-cell engagers, HIV cure antibodies with the Gates Foundation, and influenza A programs. Founded in 2016 and headquartered at 499 Illinois Street, Suite 500, in San Francisco, California, Vir Biotechnology operates primarily in the United States and Europe, targeting unmet needs in virology (hepatitis B/D, HIV, influenza, tuberculosis) and immuno-oncology with monoclonal antibodies, T-cell engagers, siRNA therapies and innate immunity modulators; it generates revenue from collaborations, grants and licenses. Recent developments include accelerated enrollment completion in the ECLIPSE 1 Phase 3 trial for hepatitis delta two months ahead of schedule, ongoing momentum in ECLIPSE 2 and 3 trials positioning for regulatory submissions, a planned comprehensive data update for influenza A candidate VIR-5500 in Q1 2026, expansion into first-line prostate cancer via a VIR-5500/ARPI combination study, a $250 million funding round at a $4.2 billion valuation bringing total raised to $821 million, and sustained strategic partnerships with GlaxoSmithKline, Alnylam Pharmaceuticals, Brii Biosciences, MedImmune and Sanofi to support pipeline advancement.
Company News
Critical Survey: REGENXBIO (NASDAQ:RGNX) versus Vir Biotechnology (NASDAQ:VIR)
Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?
Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments
Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors
Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer
uniQure (NASDAQ:QURE) and Vir Biotechnology (NASDAQ:VIR) Critical Review
Vir Biotechnology Appoints David Liu as Chief Medical Officer
Vir Biotechnology Appoints David Liu as Chief Medical Officer
Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD's The Liver Meeting® 2026
Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer
Vir Biotechnology: Astellas Deal Highlights The Platform's Value
Engineers Gate Manager LP Sells 121,964 Shares of Vir Biotechnology, Inc. $VIR
Head-To-Head Comparison: Crescent Biopharma (NASDAQ:CBIO) vs. Vir Biotechnology (NASDAQ:VIR)
Bank of New York Mellon Corp Makes New $7.08 Million Investment in Vir Biotechnology, Inc. $VIR
Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Algert Global LLC Purchases 315,969 Shares of Vir Biotechnology, Inc. $VIR
ADAR1 Capital Management LLC Acquires New Shares in Vir Biotechnology, Inc. $VIR
Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Transcript
Vir Biotechnology Q2 Earnings Call Highlights
Vir Biotechnology Q2 Earnings Call Highlights